Trials / Completed
CompletedNCT01332435
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 6,896 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This retrospective study aims to assess the economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI and alpha-blocker (AB) combination therapy. Both the Integrated Health Care Information Solutions and PharMetrics databases will be utilized for this study (2000-2007).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5ARI + AB | 5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2011-04-11
- Last updated
- 2017-06-27
- Results posted
- 2011-07-22
Source: ClinicalTrials.gov record NCT01332435. Inclusion in this directory is not an endorsement.